Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

InMed Conferences and Events

Upcoming Events

Past Events

H.C. Wainwright Global Investment Conference

Date: May 23-26, 2022

Presentation: The webcast recording will available on this page. Please check back for the link to access the webcast.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your H.C. Wainwright institutional representative.

More information about the H.C. Wainwright Global Investment Conference can be found here.

Add to Calendar

Canaccord Genuity’s 6th Annual Global Cannabis Conference

Date: May 11, 2022

Presentation: The webcast recording will be posted on this page. Check back for the link.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Canaccord institutional representative. More information on the Canaccord Cannabis Conference can be found here.

Add to Calendar

Benzinga Spring 2022 Cannabis Capital Conference

Date: April 20-21, 2022

Management will be available for virtual one-on-one meetings with institutions and industry representatives. To request 1-on-1 meetings with the Company please contact investor relations at [email protected]

Add to Calendar

InMed Presenting at 34th Annual Roth Conference

Date: March 13-15, 2022

InMed Pharmaceuticals will be presenting at the upcoming 34th Annual Roth Conference in Orange Country, CA March 13-15, 2022.

Watch the fireside chat with InMed CEO, Eric A. Adams and Roth Analyst Scott Henry:

https://wsw.com/webcast/roth43/inm2/1748056

InMed Presentation webcast link: https://wsw.com/webcast/roth43/inm/1677456

Roth Conference website

Add to Calendar

Conference Call and Webcast: InMed’s Second Quarter Fiscal 2022 Financial Results and Business Update

Date: Tuesday, February 15, 2022

Time: 11:00am PT / 2:00pm ET

Conference Call & Webcast*:

Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern Time
US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 8645175
Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv
(*Webcast replay available for 90 days)

The Company’s full financial statements and related MD&A for the second quarter of fiscal year 2022, ended December 31, 2021 will be available at www.inmedpharma.com, www.sedar.com  and at www.sec.gov on February 15, 2022.

Add to Calendar

InMed presenting at the KCSA Cannabis Virtual Investor Conference

Date: Thursday, January 20, 2022

Time: 1:30pm ET

InMed presenting at the KCSA Cannabis Virtual Investor Conference this Thursday at 1:30pm ET. President and CEO, Eric A. Adams to present.

Register free to participate. https://www.virtualinvestorconferences.com/events/event-details/kcsa-cannabis-virtual-investor-conference-0?utm_source=Virtual+Investor+Conference

Add to Calendar

Tribe Public Event “Addressing The Increasing Demand For Rare Cannabinoids”

Date: January 6, 2022

Time: 8:00am PT/ 11:00am ET

We are excited to be hosting Tribe Public’s Next Webinar Presentation and Q&A Event which will be held Thursday, January 6, 2022 (8 am PT/ 11 am ET). Our events are approximately 30 minutes in duration.

Eric A. Adams, CEO & President of InMed Pharmaceuticals, SVP, General Manager of BayMedica Shane Johnson, & VP, Commercial Operations Chris Meiering, PhD will co-host a presentation and Q&A event titled “Addressing The Increasing Demand For Rare Cannabinoids”. There will be a 5-10 minute Q&A session at the end of the presentation, so please send your questions for management to Tribe’s email: [email protected]

Register for the event here.

Add to Calendar

Cowen 4th Annual Cannabis Conference

Date: November 29th – December 1st, 2021

Time: 8:00 am

InMed Pharmaceuticals will be attending Cowen’s 4th Annual Cannabis Conference.  The company will be conducting virtual one-on-one meetings.

This three-day conference will comprise topical panel discussions with C-Suite presenters hosted by Cowen Research and Washington Research Group analysts & along with virtual one-on-one meetings.

*Cowen conferences and events are intended for institutional clients and corporate clients of the firm.  They are not open to media or retail investors.

For more information on the conference, visit Cowen’s webpage at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/

Add to Calendar

InMed Pharmaceuticals’ Eric Hsu joins panel discussion at Benzinga Healthcare Small Cap Conference

Date: September 29th, 2021

Time: 11:55am ET

InMed Pharmaceuticals’ Eric Hsu, Senior Vice President of Preclinical Research and Development, will join the panel discussion “Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases”

To learn more about the Benzinga Healthcare Conference and tune into the panel discussion, join here: https://www.benzinga.com/events/small-cap/healthcare/

Add to Calendar

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

Date: Friday, September 24, 2021

Time: 8:00 AM Pacific Time, 11:00 AM Eastern Time

InMed Pharmaceuticals will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021.

US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 9373618
Webcast: https://edge.media-server.com/mmc/p/ny89uo2r
(*Webcast replay available for 90 days)

The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021 will be available at www.inmedpharma.com, www.sedar.com and at www.sec.gov on September 24, 2021.

Add to Calendar
Load More


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent